AB 2209
9 links on this map: who funds them, what they touched, and who lobbied on it. Select anyone to move the map to them.
Start with
and connect to
Browse all held record sources
Zoom to read. Drag to explore. Select a connection.
Every link on this map
The same connections as a table, with the reason each one is here.
| Astellas Pharma US, Inc. | Lobbied on it | Astellas Pharma US, Inc. named AB 2209 in 2 lobbying reports. | 2 reports |
| Astrazeneca Pharmaceuticals, LP | Lobbied on it | Astrazeneca Pharmaceuticals, LP named AB 2209 in 2 lobbying reports. | 2 reports |
| California Life Sciences | Lobbied on it | California Life Sciences named AB 2209 in 2 lobbying reports. | 2 reports |
| Millennium Pharmaceuticals Inc. | Lobbied on it | Millennium Pharmaceuticals Inc. named AB 2209 in 2 lobbying reports. | 2 reports |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Lobbied on it | Boehringer Ingelheim Pharmaceuticals, Inc. named AB 2209 in 1 lobbying report. | 1 report |
| Celgene Corporation | Lobbied on it | Celgene Corporation named AB 2209 in 1 lobbying report. | 1 report |
| GSK | Lobbied on it | GSK named AB 2209 in 1 lobbying report. | 1 report |
| Molina Healthcare of California | Lobbied on it | Molina Healthcare of California named AB 2209 in 1 lobbying report. | 1 report |
| Health care coverage: clinical pathways. | Source records | AB 2209 has an explicit source reference to Health care coverage: clinical pathways.. | None |
In the news
Reporting about the selected subject. Articles are context and do not establish a connection on this map.
Loading coverage…